Proinflammatory homeobox gene, ISX, regulates tumor growth and survival in hepatocellular carcinoma

Cancer Research

Volumn 73, Issue 2, 2013, Pages 508-518

  Hsu, Shih Hsien ^a   Wang, Li Ting ^a   Lee, King Teh ^a,c   Chen, Yao Li ^e,f   Liu, Kwei Yan ^a   Suen, Jau Ling ^a   Chai, Chee Yin ^b   Wang, Shen Nien ^a,c,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b Department of Pathology ^*  (Taiwan)

^c Department of Surgery   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; INTERLEUKIN 6; SHORT HAIRPIN RNA;

ADULT; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; GENE EXPRESSION; HOMEOBOX; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISX GENE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN D1; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, HOMEOBOX; HOMEODOMAIN PROTEINS; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 84872510224     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2795     Document Type: Article

References (33)

1. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009;44 Suppl 19: 136-41.
2. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009;220: 292-6.
3. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11: 558-72.
4. Matsushime H, Ewen ME, Strom DK, Kato J-Y, Hanks SK, RousselMF, et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992;71: 323-34.
5. Bates S, Parry D, Bonetta L, Vousden K, Dickson C, Peters G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene 1994;9: 1633-40.
6. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12: 2245-62.
7. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34: 207-18.
8. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994;13: 2124-30.
9. Opitz OG, Harada H, Suliman Y, Rhoades B, Sharpless NE, Kent R, et al. A mouse model of human oral-esophageal cancer. J Clin Invest 2002;110: 761-9.
10. Levine M, Hoey T. Homeobox proteins as sequence-specific transcription factors. Cell 1988;55: 537-40.
11. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2: 777-85.
12. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR. The pathophysiology ofHOXgenes and their role in cancer. J Pathol 2005;205: 154-71.
13. Del Bene F, Wittbrodt J. Cell cycle control by homeobox genes in development and disease. Semin Cell Dev Biol 2005;16: 449-60.
14. Seino Y, Miki T, Kiyonari H, Abe T, Fujimoto W, Kimura K, et al. Isx Participates in the Maintenance of VitaminAMetabolism by Regulation of {beta}-Carotene 15,150-Monooxygenase (Bcmo1) Expression. J Biol Chem 2008;283: 4905-11.
15. Wang LT, Lin CS, Chai CY, Liu KY, Chen JY, Hsu SH. Functional interaction of Ugene and EBV infection mediates tumorigenic effects. Oncogene 2011;30: 2921-32.
16. Su WH, Chao CC, Yeh SH, Chen DS, Chen PJ, Jou YS. OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res 2007;35:D727-31.
17. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374: 1-20.
18. Cheng KS, Tang HL, Chou FT, Chou JW, Hsu CH, Yu CJ, et al.Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. Hepatogastroenterology 2009;56: 1105-10.
19. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009;124: 2766-70.
20. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88- dependent IL-6 production. Science 2007;317: 121-4.
21. Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010;7: 41-9.
22. Kanai M, Hamada J, Takada M, Asano T, Murakawa K, Takahashi Y, et al. Aberrant expressions of HOX genes in colorectal and hepatocellular carcinomas. Oncol Rep 2010;23: 843-51.
23. Shimoda M, Takahashi M, Yoshimoto T, Kono T, Ikai I, Kubo H. A homeobox protein, prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma. Clin Cancer Res 2006;12: 6005-11.
24. Zhu R, Wong KF, Lee NP, Lee KF, Luk JM. HNF1alpha and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem 2010;111: 618-26.
25. Kumar S, Duester G. SnapShot: retinoic acid signaling. Cell 2011;147: 1422. e1.
26. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1: 181-93.
27. Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 1984;73: 1389-93.
28. Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol 2010;134: 237-50.
29. Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000;10: 211-31.
30. Brechot C. Hepatitis B virus (HBV) and hepatocellular carcinoma. HBV DNA status and its implications. J Hepatol 1987;4: 269-79.
31. Sanz E, Hofer MJ, Unzeta M, Campbell IL. Minimal role for STAT1 in interleukin-6 signaling and actions in the murine brain. Glia 2008; 56: 190-9.
32. Wallenius V, Wallenius K, Jansson JO. Normal pharmacologicallyinduced, but decreased regenerative liver growth in interleukin-6- deficient (IL-6(-/-)) mice. J Hepatol 2000;33: 967-74.
33. Debonera F, Wang G, Xie J, Que X, Gelman A, Leclair C, et al. Severe preservation injury induces Il-6/STAT3 activation with lack of cell cycle progression after partial liver graft transplantation. Am J Transplant 2004;4: 1964-71.